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Ischemia–reperfusion (I/R) injury is one of the major mechanisms behind organ dysfunction and failure after 
myocardial infarction, stroke, and transplantation. In the 
postischemic inflammatory response, leukocytes accumulate 
in the microvasculature and compromise reperfusion of the 
injured tissue. Extravasating leukocytes release reactive oxy-
gen species, cytokines, and proteases, which promotes micro-
vascular leakage and amplifies the ischemic tissue injury.1,2 
Concomitantly, leukocytes phagocytose apoptotic/necrotic 
cells and produce anti-inflammatory factors that actively 
contribute to tissue regeneration and healing3 collectively 
emphasizing leukocytes as key players in the pathogenesis 
of I/R injury.
See accompanying editorial on page 695
Fibrinolysis is a fundamental biological process that 
enables the maintenance of tissue perfusion by preventing clot 
formation in blood vessels. Plasmin is the principal effector 
protease in the fibrinolytic system mediating the dissolution of 
fibrin polymers. Its zymogen form, plasminogen, is activated by 
tPA (tissue-type plasminogen activator) and, to a much lesser 
degree, by urokinase-type plasminogen activator. Beyond their 
established role in the fibrinolytic system, these serine prote-
ases have previously been documented to contribute to differ-
ent biological processes,4–7 including the regulation of distinct 
steps in leukocyte recruitment to postischemic tissue.8–11
Plasminogen activator inhibitor-1 (PAI-1) is the principal 
inhibitor of the plasminogen activators limiting exaggerated 
fibrinolytic activity. Secreted by hepatocytes and microvas-
cular endothelial cells, PAI-1 is primarily found circulating 
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Objective—Ischemia–reperfusion (I/R) injury significantly contributes to organ dysfunction and failure after myocardial 
infarction, stroke, and transplantation. In addition to its established role in the fibrinolytic system, plasminogen activator 
inhibitor-1 has recently been implicated in the pathogenesis of I/R injury. The underlying mechanisms remain largely obscure.
Approach and Results—Using different in vivo microscopy techniques as well as ex vivo analyses and in vitro assays, we 
identified that plasminogen activator inhibitor-1 rapidly accumulates on microvascular endothelial cells on I/R enabling 
this protease inhibitor to exhibit previously unrecognized functional properties by inducing an increase in the affinity of 
β2 integrins in intravascularly rolling neutrophils. These events are mediated through low-density lipoprotein receptor–
related protein-1 and mitogen-activated protein kinase–dependent signaling pathways that initiate intravascular adherence 
of these immune cells to the microvascular endothelium. Subsequent to this process, extravasating neutrophils disrupt 
endothelial junctions and promote the postischemic microvascular leakage. Conversely, deficiency of plasminogen activator 
inhibitor-1 effectively reversed leukocyte infiltration, microvascular dysfunction, and tissue injury on experimental I/R 
without exhibiting side effects on microvascular hemostasis.
Conclusions—Our experimental data provide novel insights into the nonfibrinolytic properties of the fibrinolytic system and 
emphasize plasminogen activator inhibitor-1 as a promising target for the prevention and treatment of I/R injury.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38: 
829-842. DOI: 10.1161/ATVBAHA.117.309760.)
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in the blood. In addition to its well-known antifibrinolytic 
properties, also PAI-1 has been implicated in nonfibrinolytic 
processes, such as cell adhesion and migration.4,12,13 In the 
context of I/R, elevated levels of PAI-1 have been reported 
to be an independent risk factor for ischemic cardiovascular 
events.14–17 The functional role of PAI-1 in the pathogenesis of 
I/R injury, however, remained largely unclear.
In the present study, we demonstrate that PAI-1 plays a piv-
otal role during the initiation of the postischemic inflammatory 
response by directing neutrophils to the site of injury: Subsequent 
to a rapid immobilization on the postischemic microvascular 
endothelium, this protease inhibitor induces affinity changes of 
β2 integrins in intravascularly rolling neutrophils which promote 
the accumulation of these immune cells in the reperfused tissue. 
Interfering with these, PAI-1–dependent events effectively atten-
uated leukocyte infiltration, microvascular dysfunction, and tis-
sue injury on experimental I/R without exhibiting side effects on 
microvascular hemostasis. Our experimental data provide novel 
insights into the nonfibrinolytic properties of the fibrinolytic sys-
tem and propose the inhibition of PAI-1 as a promising strategy 
for the prevention and treatment of I/R injury.
Materials and Methods
Animals
Male C57BL/6J mice were purchased from Charles River (Sulzfeld, 
Germany). PAI-1–deficient mice (backcrossed for >10 generations on 
a C57BL/6J background) were generated at the Jackson Laboratory 
(Bar Harbor) and purchased from Charles River. All experiments 
were performed with male mice at the age of 10–12 weeks. Animals 
were held under standard laboratory conditions with free access to 
animal chow and water. All experiments were performed according 
to the German legislation for the protection of animals (approved by 
the government of Upper Bavaria).
Surgical Procedures
M. Cremaster Assay
The surgical preparation of the cremaster muscle was performed as 
originally described by Baez18 with minor modifications. Mice were 
anesthetized using a ketamine/xylazine mixture (100 mg/kg ketamine 
and 10 mg/kg xylazine), administered by IP injection. The left femoral 
artery was cannulated in a retrograde manner (polyethylene- 10, inner 
diameter 0.28 mm; Portex, Hythe, UK) for administration of micro-
spheres and drugs. The right cremaster muscle was exposed through 
a ventral incision of the scrotum. The muscle was opened ventrally 
in a relatively avascular zone, using careful electrocautery to stop any 
bleeding and spread over the transparent pedestal of a custom-made 
microscopy stage. Epididymis and testicle were detached from the 
cremaster muscle and replaced into the abdominal cavity. Throughout 
the procedure and after surgical preparation during in vivo micros-
copy, the muscle was superfused with warm-buffered saline.
Hepatic I/R Injury
Warm ischemia of the left liver lobe was induced for 90 minutes by 
reversible clamping of the supplying vessels as described previously.9 
Tissue and blood samples were taken at the end of the experiment 
after 120 minutes of reperfusion. Blood samples were immediately 
centrifuged at 2000g for 10 minutes and stored at −80°C. Serum 
aspartate aminotransferase (AST) and alanine transaminase (ALT) 
activities were measured with an automated analyzer (Hitachi 917; 
Roche-Boehringer Mannheim, Co, Germany) using standardized test 
systems (HiCo GOT and HiCo GPT; Roche-Boehringer Mannheim, 
Co).
In Vivo Microscopy
The setup for in vivo microscopic analyses of leukocyte recruitment 
and microvascular permeability was centered around an AxioTech-
Vario 100 Microscope (Zeiss MicroImaging GmbH, Göttingen, 
Germany), equipped with a Colibiri LED light source (Zeiss 
MicroImaging GmbH) for fluorescence epi-illumination microscopy. 
For fluorescein isothiocyanate (FITC)–dextran excitation or reflected 
oblique light illumination, 470 or 625 nm were used, respectively. 
Light was directed onto the specimen via filter set 62 high efficiency 
(HE; Zeiss MicroImaging GmbH) fitted with dichroic and emission 
filters (TFT 495+610 [HE]; tunable bandpass 527+LP615 [HE]). 
Microscopy images were obtained with an AxioCam Hsm digital 
camera using a ×20 water immersion lens (0.5 numeric aperture 
[NA]; Zeiss MicoImaging Gmbh). Reflected light oblique transillu-
mination was obtained by positioning a mirroring surface (reflector) 
directly below the specimen and tilting its angle relative to the hori-
zontal plane. The reflector consisted of a round cover glass (thick-
ness, 0.19–0.22 mm; diameter, 11.8 mm), which was coated with 
aluminum vapor (Freichel, Kaufbeuren, Germany) and brought into 
direct contact with the overlying specimen as described previously.19
The set-up for in vivo microscopic analyses of phototoxic injury–
induced microvascular thrombosis was centered around an Olympus 
BX 50 upright microscope (Olympus Microscopy, Hamburg, 
Germany). Light from a 75-W xenon source was narrowed to a near 
monochromatic beam of a wavelength of 488 nm by a galvanomet-
ric scanner (Polychrome II; TILL Photonics, Gräfelfing, Germany) 
and directed onto the specimen via a FITC filter cube equipped 
with dichroic and emission filters (DCLP 500, LP515; Olympus 
Microscopy). Microscopic images were obtained with Olympus 
water immersion lenses (×20/NA 0.5 and 60×/NA 0.9), recorded with 
a charge-coupled device camera (IMAGO S/N 382KLO345; TILL 
Photonics GmbH, Gräfelfing, Germany) and subjected to digital 
image analysis (TILLvisION 4.0; TILL Photonics GmbH).
For measurement of centerline blood flow velocity, green fluores-
cent microspheres (0.96 µm diameter; Molecular Probes, Leiden, The 
Netherlands) were injected via the femoral artery catheter, and their 
passage through the vessels of interest was recorded in both micros-
copy set-ups employed, using the FITC filter cube under appropriate 
stroboscopic illumination (exposure, 1 ms; cycle time, 10 ms; l=488 
nm), integrating video images for sufficient time (0.80 ms) to allow 
for the recording of several images of the same bead on one frame. 
Beads that were flowing freely along the centerline of the vessels 
were used to determine blood flow velocity.
Quantification of Leukocyte Kinetics and 
Microhemodynamic Parameters
Off-line analysis of parameters describing the sequential steps of leu-
kocyte extravasation was performed with AxioVision 4.6 software 
(Zeiss MicroImaging GmbH). ImageJ software (National Institutes 
of Health, Bethesda, MD) was used for further image processing and 
analysis. Rolling leukocytes were defined as those moving slower 
than the associated blood flow and quantified for 30 seconds. Firmly 
adherent cells were determined as those resting in the associated blood 
flow for >30 seconds and related to the luminal surface per 100-μm 
vessel length. Transmigrated cells were counted in regions of inter-
est, covering 75 μm on both sides of a vessel >100 μm vessel length. 
By measuring the distance between several images of one fluorescent 
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Figure 1. Role of plasminogen activator inhibitor-1 (PAI-1) for postischemic leukocyte responses. Using confocal microscopy, distribution 
of PAI-1 was analyzed in postcapillary venules of the cremaster muscle of sham-operated wild-type (WT) mice or of WT mice undergoing 
ischemia-reperfusion (I/R; 30/120 min) as detailed in Material and Methods in the online-only Data Supplement. A, Representative images 
of CD31-positive (blue; endothelial cells, leukocytes) and Ly-6G–positive (red; neutrophils) cells, as well as of PAI-1 (green). Leukocyte 
recruitment to the mouse cremaster muscle was analyzed by in vivo microscopy after 30 min of ischemia and 120 min of reperfusion as 
detailed in Material and Methods in the online-only Data Supplement. B, Representative in vivo microscopy images and (Continued ) 
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bead under stroboscopic illumination, centerline blood flow veloc-
ity was determined. From measured vessel diameters and centerline 
blood flow velocity, apparent wall shear stress was calculated, assum-
ing a parabolic flow velocity profile over the vessel cross-section.
Cell Transfer Experiments
To investigate the contribution of leukocyte and non-leukocyte PAI-1 
to postischemic leukocyte responses, a cell-transfer technique was 
used as described previously.9 Leukocytes were isolated from donor 
mice by flushing the femur and tibia bones with PBS. Cells were then 
sieved and counted, resuspended in PBS containing BSA (0.25%), 
and incubated with calcein-AM (10 μmol/L final concentration at 
37°C for 30 minutes). After 2 washes, the cells were injected intrave-
nously into recipient mice via the right jugular vein (107 cells/mouse) 
120 minutes before the surgical preparation. Fluorescent cells were 
counted in 175 high power fields per animal; this being equivalent 
to the total quantifiable area of an exteriorized cremaster muscle in 
the present studies. Results are shown as the number of adherent or 
transmigrated calcein-labeled cells/high power field.
Reagents
Recombinant mouse PAI-1 and human RAP (Molecular Innovations, 
Novi, MI). Anti-LRP-1 antibody (α2-M-R/LRP1/CD91; polyclonal; 
BioMac, Leipzig, Germany). Neutrophil-depleting anti-Ly-6G mono-
clonal antibody (clone 1A8; 100 μg IV 24 and 6 hours before induc-
tion of inflammation; BD Biosciences, San Jose, CA). FITC dextran 
(150 kDa; Sigma-Aldrich, Deisenhofen, Germany).
Experimental Groups
Animals were assigned to the following groups: sham-operated wild-
type (WT) mice as well as WT mice, PAI-1−/− mice, and WT mice 
treated 5 minutes before reperfusion with anti-LRP-1 antibody, the 
PAI-1 inhibitor TM5275 (40 mg/kg body weight; IA), or isotype 
control/vehicle undergoing I/R (30/120 min; n=4–6 each group). 
Moreover, leukocyte responses were analyzed in the cremaster mus-
cle of WT mice receiving fluorescent leukocytes from WT or PAI-
1−/− donors and of PAI-1−/− mice receiving fluorescent leukocytes from 
WT donors undergoing I/R (30/120 min; n=5 each group). In another 
set of experiments, WT mice received PBS (200 μL; supplemented 
with 0.01 % BSA), different doses of murine (active) PAI-1 (0.01, 0.1, 
1.0 µg; diluted in 200 µL PBS supplemented with 0.01% BSA), or 
latent (inactive) PAI-1 (1.0 µg; diluted in 200 µL PBS supplemented 
with 0.01% BSA) administered by intrascrotal injection (n=4 each 
group). Additional experiments were performed in WT mice receiving 
RAP, anti-LRP-1 antibody, or drug vehicle/isotype control undergoing 
stimulation with recombinant murine PAI-1 (1.0 µg intrascrotal; n=5 
each group). Further experiments were performed in WT mice either 
pretreated with the neutrophil-depleting monoclonal anti-Ly-6G anti-
body 1A8 or isotype control undergoing stimulation with recombi-
nant murine PAI-1 (1.0 µg intrascrotal; n=6 each group). In additional 
experiments, phototoxic injury-induced thrombosis (see below) was 
induced in WT and PAI-1−/− mice (n=5 each group). In a final set 
of experiments, warm hepatic I/R (90/120 minutes) was induced in 
sham-operated WT mice, as well as in WT mice, in PAI-1−/− mice, 
or in WT mice treated with TM5275 or vehicle (n=4–6 each group).
I/R Injury
For the analysis of I/R-elicited leukocyte responses, 3 postcapillary 
vessel segments in a central area of the spread-out cremaster muscle 
were randomly chosen among those that were at least 150 mm away 
from neighboring postcapillary venules and did not branch over a 
distance of at least 150 µm. After having obtained baseline record-
ings of leukocyte rolling, firm adhesion, and transmigration in all 3 
vessel segments, ischemia was induced by clamping all supplying 
vessels at the basis of the cremaster muscle using a vascular clamp 
(Martin, Tuttlingen, Germany) as described previously.9 Stagnancy of 
blood flow was then verified by in vivo microscopy. After 30 minutes 
of ischemia, the vascular clamp was removed, and reperfusion was 
restored for 120 minutes. Measurements, which took about 5 min-
utes, respectively, were repeated at 60 and 120 minutes after the onset 
of reperfusion.
After in vivo microscopy, tissue samples of the cremaster 
muscle were taken for immunohistochemistry. Blood samples 
were collected by cardiac puncture for the determination of sys-
temic leukocyte counts using a Coulter ACT Counter (Coulter, 
Corp, Miami, FL). Anesthetized animals were then killed by 
exsanguination.
Neutrophil Depletion
Depletion of neutrophils was accomplished by using a rat antimouse 
monoclonal antibody (anti-Ly-6G monoclonal antibody; clone 1A8; 
100 μg IV; 24 and 6 hours before the experiment). Successful neutro-
phil depletion was confirmed by flow cytometry analysis and defined 
as a reduction of circulating neutrophils by >95% compared with ani-
mals treated with an isotype control antibody.
Microvascular Permeability
As a measure of microvascular permeability, leakage of the macro-
molecule FITC dextran (5 mg in 0.15 mL saline, IA, Mr [relative 
molecular mass] 150 kDa) was analyzed as described previously.9 
Thirty minutes after application of FITC dextran, 6 randomly cho-
sen postcapillary vessel segments and the surrounding perivascular 
tissue was excited at 488 nm, and emission 515 nm was recorded 
by an AxioCam Hsm digital camera (Zeiss MicoImaging GmbH, 
Germany) using an appropriate emission filter (LP 515). Mean gray 
values of fluorescence intensity were measured by digital image anal-
ysis (ImageJ Software; National Institutes of Health) in 6 randomly 
selected regions of interest (50×50 µm2), localized 50 µm distant from 
the postcapillary venule under investigation.
Macromolecular Permeability of Human 
Microvascular Endothelial Cell Lines
The human dermal microvascular endothelial cell line CDC/
EU.HMEC-1 was kindly provided by the US Centers for Disease 
Control and Prevention (DCD; Atlanta, GA). Human microvascu-
lar endothelial cell lines (HMECs) are proven to preserve morphol-
ogy, phenotype, and functionality of normal human microvascular 
ECs.20 HMECs were cultured in endothelial growth medium (ECGM; 
Provitro, Berlin, Germany) containing 10% heat-inactivated fetal calf 
serum (Biochrom, Berlin, Germany), penicillin (100 U/mL)/strepto-
mycin (100 μg/mL), and amphotericin B (0.25 μg/mL) at 37°C in 
humidified air with 5% CO
2
.
HMECs were cultured on 12-well Transwell inserts (pore size 
0.4 μm; Corning, New York, NY). FITC dextran (40 kDa; 1 mg/mL; 
Sigma-Aldrich) was given to the upper compartment at t=0 minutes, 
and cells were treated as indicated. RAP (100 ng/mL) was applied 
15 minutes before PAI-1. Samples were taken from the lower com-
partment at t=60 min. The fluorescence (λex: 485 nm; λem: 535 nm) 
Figure 1 Continued. quantitative data for intravascular adherence and transmigration of leukocytes (>85% Ly-6G–positive neutrophils) 
to the postischemic tissue in sham-operated WT mice and in WT or PAI-1–deficient mice undergoing I/R (mean±SEM for n=4 per group; 
#P<0.05, vs sham; *P<0.05, vs WT). Adherence and transmigration of calcein AM-labeled bone marrow leukocytes were quantified in the 
cremaster muscle after 30 min of ischemia and 120 min of reperfusion using in vivo fluorescence microscopy as detailed in Material and 
Methods in the online-only Data Supplement. C, Results for WT mice receiving leukocytes from WT or PAI-1–deficient donors as well as 
for PAI-1–deficient mice receiving leukocytes from WT or PAI-1–deficient donors (mean±SEM for n=6 per group; *P<0.05, vs WT→WT).
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increase of the samples was detected with a SpectraFluorPlus plate 
reader (Tecan, Crailsheim, Germany). All experiments were indepen-
dently performed for at least 3 times.
Phototoxic Injury–Induced Thrombosis
Phototoxic injury–induced thrombosis was performed in cremas-
teric arterioles and venules as described earlier.21 Light intensity 
Figure 2. Mechanisms underlying plasminogen activator inhibitor-1 (PAI-1)–elicited leukocyte responses. Using in vivo microscopy on the 
cremaster muscle of WT mice, leukocyte recruitment was analyzed on intrascrotal injection of varying doses of recombinant murine PAI-1 
or vehicle as detailed in Material and Methods in the online-only Data Supplement. A, Quantitative data for intravascular rolling and firm 
adherence as well as transmigration of leukocytes (>85% Ly-6G–positive neutrophils) to the perivascular tissue. B–D, Quantitative data 
for intravascular rolling and firm adherence as well as transmigration of leukocytes obtained in wild-type (WT) mice receiving an intra-
arterial injection of RAP (receptor-associated protein), anti–LRP-1 (low-density lipoprotein receptor–related protein-1) Abs, anti-LFA-1 
(lymphocyte function-associated antigen-1)/CD11a mAbs, anti-Mac-1/CD11b mAbs, or vehicle/isotype control as well as an intrascrotal 
injection of 1μg PAI-1 (mean±SEM for n=5 per group; #P<0.05, vs control/unstimulated; *P<0.05, vs vehicle/isotype control).
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values were measured by a photodiode at 488 nm at the exit of the 
light source in each experiment before induction of thrombosis and 
maintained between 2.65 and 2.75 mA. After surgical preparation of 
the cremaster muscle, appropriate microvessels were chosen, cen-
terline blood flow velocity was determined as described above, and, 
subsequently, FITC dextran was applied. Five minutes later, pho-
toactivation was induced by exposing a vessel segment of 300 µm 
length to continuous epi-illumination with a wavelength of 488 nm 
using an Olympus water immersion lens (×60/NA 0.9). Thrombus 
formation was quantified in one venule (30–50 µm in diameter) and 
in one arteriole (25–35 µm in diameter) per experiment. Onset time 
of thrombus formation is defined by the time when first platelets 
became adherent to the vessel wall. Cessation time of blood flow 
is defined as the time required for complete occlusion of the ves-
sel. Occlusion time in vessels without complete occlusion until the 
end of the recording was considered 20 minutes for venules and 40 
minutes for arterioles.
Figure 3. Effect of plasminogen activator inhibitor-1 (PAI-1) on activation of neutrophils. As a measure of conformational changes in 
neutrophil integrins, binding of intercellular adhesion molecule (ICAM)-1/CD54 or vascular cell adhesion molecule (VCAM)-1/CD106 was 
analyzed in neutrophils isolated from the peripheral blood of wild-type mice by multichannel flow cytometry as detailed in Material and 
Methods in the online-only Data Supplement. A, Gating strategy for identifying neutrophils. B, Quantitative data for surface expression 
of CD18 and (C and D) for the binding of ICAM-1/CD54 or VCAM-1/CD106 to neutrophils pre-incubated with RAP (receptor-associated 
protein), anti–LRP-1 (low-density lipoprotein receptor–related protein-1) Abs, different mitogen-activated protein kinase (MAPK) inhibitors, 
or vehicle/isotype control Abs (mean±SEM for n=4–6 per group; #P<0.05, vs control; *P<0.05, vs vehicle/isotype control). APC indicates 
allophycocyanin; FITC, fluorescein isothiocyanate; and SSC, side-scattered light.
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Microvascular Fibrin(ogen) Deposition
Deposition of fibrin(ogen) on microvascular endothelial cells was 
determined in a separate set of experiments by in vivo fluores-
cence microscopy as demonstrated before with minor modifica-
tions.10 Briefly, Alexa 488–conjugated human fibrinogen (17 mg/kg; 
Molecular Probes, Eugene, OR) was administered IA 5 minutes after 
induction of ischemia. To assess the microvascular distribution of 
fibrin(ogen), 3 to 5 postcapillary venules in the cremaster muscle or 
5 high power fields of sinusoids in the liver were randomly analyzed 
in WT and PAI-1–deficient animals undergoing I/R (30/90-minute 
ischemia and 120-minute reperfusion; n=3 per group). Deposition of 
Alexa 488–conjugated fibrin(ogen) was analyzed by measuring fluo-
rescence intensity profiles using Image J software (National Institutes 
of Health).
(Immuno)histochemistry
To determine the phenotype of transmigrated leukocytes, immunos-
taining of paraffin-embedded serial tissue sections of the cremaster 
muscle or the liver was performed. Sections were incubated with 
primary rat antimouse anti-Ly-6G, anti-CD45 (BD Biosciences), 
anti-F4/80 (Serotec, Oxford, UK) IgG, or isotype control antibod-
ies. Afterwards, the paraffin sections were stained with commer-
cially available immunohistochemistry kits (Ly-6G, CD45, Super 
Sensitive Link-Label IHC detection system; BioGenex, San Ramon, 
CA; F4/80, Vectastain ABC kit, Vector Laboratories, Burlingame, 
CA), obtaining an easily detectable reddish or brownish end product, 
respectively, or fluorescence-labeled secondary antibodies. Finally, 
the sections were counterstained with Mayer hemalaun. The num-
ber of extravascularly localized Ly-6G-, CD45-, or F4/80-positive 
cells was quantified by light microscopy (magnification ×400) on 3 
sections (10 observation fields per section) from 6 individual ani-
mals per experimental group in a blinded manner. The number of 
transmigrated Ly-6G–positive cells (neutrophils) and F4/80-positive 
cells (monocytes/macrophages) is expressed as the percentage of 
total CD45-positive leukocytes.
Paraffin-embedded liver sections were also stained by termi-
nal deoxynucleotidyl transferase-mediated deoxyuridine triphos-
phate-digoxenin nick-end labeling (TUNEL) using a commercially 
available kit (Roche-Boehringer Mannheim, Co, Germany). TUNEL-
positive cells were counted in a blinded manner using light micros-
copy (magnification 400×) in 10 high power fields.
Confocal Microscopy
For the analysis of PAI-1 deposition, cremaster muscles were pre-
pared as described previously.9 After incubation with an anti-Ly6G 
antibody (Invitrogen, Carlsbad, CA), an Alexa Fluor 647 anti-
CD31 monoclonal antibody (Invitrogen), and a rabbit anti-mouse 
anti-PAI-1 antibody (Abcam, Cambridge, UK), tissues were incu-
bated with the secondary Alexa Fluor 488–linked goat antirat or 
Alexa Fluor 546–linked goat antirabbit antibody (Invitrogen). 
Immunostained tissues were mounted in PermaFluor (Beckman 
Coulter, Fullerton, CA) on glass slides and observed using a Leica 
SP5 confocal laser-scanning microscope (Leica Microsystems, 
Wetzlar, Germany).
Liver Enzymes
Whole-blood samples were collected via cardiac puncture at the 
end of the experiment and immediately centrifuged at 2000g for 
10 minutes. Supernatant plasma was retrieved and stored at −80°C. 
Serum AST and ALT activities were determined at 37°C with an 
automated analyzer (Hitachi 917; Roche-Boehringer, Mannheim, 
Germany) using standardized test systems (HiCo GOT and HiCo 
GPT; Roche-Boehringer).
Figure 4. Role of plasminogen activator inhibitor-1 (PAI-1) for postischemic microvascular leakage. As a measure of microvascular leak-
age, extravasation of fluorescein isothiocyanate (FITC) dextran was analyzed in the cremaster muscle of wild-type (WT) mice by fluores-
cence in vivo microscopy as detailed in Material and Methods in the online-only Data Supplement, representative images are shown (A). 
Panels show quantitative data for FITC dextran leakage in sham-operated WT mice as well as in WT or PAI-1–deficient mice undergoing 
I/R (30/150 min) and in unstimulated WT mice as well as in WT mice treated with neutrophil-depleting anti-Ly-6G mAbs or isotype con-
trol Abs undergoing intrascrotal stimulation with recombinant murine PAI-1 (B; mean±SEM for n=4–6 per group; #P<0.05, vs sham/PBS; 
*P<0.05, vs WT/vehicle/isotype control). Macromolecular permeability for FITC dextran was analyzed in vitro in confluent HMEC (human 
microvascular endothelial cell line-1) layers as detailed in Material and Methods in the online-only Data Supplement. B, Quantitative data 
for cell layers exposed to varying doses of recombinant human PAI-1 as well as RAP (receptor-associated protein) or vehicle (mean±SEM 
for n=3–4 per group; *P<0.05, vs PBS).
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Viability of Hepatocytes
Potential direct cytoxic or cytoprotective effects of PAI-1 were deter-
mined by Alamar Blue reduction assays with primary murine hepa-
tocytes as described previously.22 Briefly, hepatocytes were isolated 
from C57BL/6 mice by liver perfusion and percoll density centrifu-
gation and seeded into gelatin-coated multiwell plates in William E 
complete medium supplemented with 50 ng/mL epidermal growth 
factor, 1 μg/mL insulin, 10 μg/mL transferrin, and 1.3 μg/mL hydro-
cortisone (all from Sigma-Aldrich, Taufkirchen, Germany). Adhesion 
was allowed overnight, and cells were exposed to 0 to 1000 ng/mL 
PAI-1 for 24 hours. Ten micromoles per liter Staurosporine (Sigma-
Aldrich) served as positive control death stimulus. Subsequently, the 
medium was aspirated, cells were washed, and Alamar Blue reagent 
was added. Metabolic resazurin reduction was allowed for 10 hours, 
and resorufin fluorescence was determined with a Synergy Mx 
microplate reader (BioTek, Bad Friedrichshall, Germany). Primary 
fluorescence data were calibrated on the untreated controls (100% 
viability).
Flow Cytometry
To evaluate the effect of PAI-1 on the binding of intercellular adhesion 
molecule-1 (ICAM-1)/CD54 to primary mouse neutrophils, antico-
agulated whole-blood samples of WT mice were suspended in Hanks 





Technologies, Carlsbad, CA) and incubated (for 5 minutes at 37°C) with 
different concentrations (1–100 ng/mL) of PAI-1 or phorbol myristate 
acetate (1 ng/mL) as a positive control and with PBS, in the presence 
of ICAM-1/Fc (10 μg/mL; R&D Systems), VCAM-1/fragment crystal-
lizable (Fc; 10 μg/mL; R&D Systems), and phycoerythrin-conjugated 
antihuman IgG1 (Fc-specific; Southern Biotechnology). In further exper-
iments, cells were treated with a RAP or vehicle, anti-LRP-1 antibody 
or isotype control antibody, SB203580 (25 μmol/L; Sigma Aldrich), 
Figure 5. Role of plasminogen activator inhibitor-1 (PAI-1) for hepatic ischemia-reperfusion (I/R) injury. In a model of warm hepatic I/R 
(90/120 min) injury, the number of apoptotic/necrotic (TUNEL [terminal deoxynucleotidyl transferase dUTP nick-end labeling]-positive) 
hepatocytes and the recruitment of CD45-positive leukocytes to the postischemic liver were analyzed as detailed in Material and Methods 
in the online-only Data Supplement. Panels show quantitative data for TUNEL- or CD45-positive cells (A) and for serum levels of gluta-
mate-pyruvate transaminase/alanine transaminase (ALT) or glutamate-oxalacetate transaminase/aspartate aminotransferase (AST; B) in 
sham-operated wild-type (WT) mice as well as WT and PAI-1–deficient mice (mean±SEM for n=6 per group; #P<0.05, vs sham; *P<0.05, 
vs WT). Cell death of primary hepatocytes isolated from WT mice was analyzed by Alamar Blue reduction assays as detailed in Material 
and Methods in the online-only Data Supplement. C, Quantitative data for hepatocytes exposed to varying doses of recombinant murine 
PAI-1, staurosporine (used as a positive control), or vehicle (mean±SEM for n=3 per group; #P<0.05, vs control).
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SP600125 (5 μmol/L; Sigma Aldrich), FR180204 (15 μmol/L; Sigma 
Aldrich) or vehicle. After washing, cells were labeled with antibodies 
directed against CD45, CD11b, CD115, and Gr1. Binding of ICAM-1/
CD54 or VCAM-1/CD106 was measured by a flow cytometer (Gallios, 
Beckmann Coulter). In separate experiments, expression of PAI-1 and 
LRP-1 was analyzed in neutrophils isolated from the peripheral blood 
of WT mice or in HMECS using anti-PAI-1 or LRP-1 antibodies (see 
above). The results were analyzed with FlowJo Software (Treestar).
Statistics
All in vivo experiments and data analyses were performed in a 
blinded manner.
Data analysis was performed with a statistical software pack-
age (SigmaStat for Windows; Jandel Scientific, Erkrath, Germany). 
After testing normality of data (using the Shapiro–Wilk test), the 
1-way ANOVA test followed by the Student–Newman–Keuls test (>2 
groups) or the t test (2 groups) was used for the estimation of stochas-
tic probability in intergroup comparisons. Mean values and SEM are 
given. P values <0.05 were considered significant.
Results
Role of PAI-1 for Postischemic Leukocyte Responses
To understand the role of PAI-1 in I/R injury, we first 
characterized the distribution of PAI-1 in postischemic 
tissue by immunostaining of whole mounts of the mouse 
cremaster muscle and confocal laser scanning microscopy 
analyses (Figure 1A). In response to I/R, PAI-1 was primar-
ily found on the surface of PECAM-1 (platelet endothelial 
cell adhesion molecule-1)/CD31+ venular endothelial cells 
and on Ly-6G+ neutrophils as well as extravasated into the 
perivascular tissue, whereas it was barely detected in crem-
asteric microvessels of sham-operated animals. In line with 
these results, expression of PAI-1 was low in neutrophils 
isolated from the peripheral blood of wild-type (WT) mice 
as well as in unstimulated microvascular endothelial cells 
as assessed by flow cytometry (Figure I in the online-only 
Data Supplement). On activation with tumor necrosis factor, 
in contrast, PAI-1 expression was significantly increased in 
these cells. Furthermore, expression of the PAI-1 receptor 
LRP-1 (low-density lipoprotein receptor–related protein-1) 
was significantly elevated on stimulation with tumor necro-
sis factor in neutrophils and endothelial cells (Figure II in 
the online-only Data Supplement). However, postischemic 
microvascular PAI-1 presentation was not affected by neu-
trophil depletion or antibody blockade of LRP-1 (Figure III 
in the online-only Data Supplement).
Leukocyte recruitment to postischemic tissue is a hallmark 
of I/R injury.1,2 To characterize the functional relevance of 
Figure 6. Role of plasminogen activator inhibitor-1 (PAI-1) for microvascular thrombus formation. Thrombus formation in microvessels 
of the cremaster muscle of wild-type (WT) mice was induced by phototoxic injury and analyzed by fluorescence in vivo microscopy as 
detailed in Material and Methods in the online-only Data Supplement, representative images are shown (A). Panels show quantitative 
data for the onset of thrombus formation and the cessation of blood flow in venules and arterioles of WT and PAI-1–deficient mice (B; 
mean±SEM for n=4 per group).
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PAI-1 for the single steps of the extravasation process of neu-
trophils to postischemic tissue, we used near-infrared reflected 
light oblique transillumination in vivo microscopy in the cre-
master muscle of WT and PAI-1–deficient mice (Figure 1B). 
As well-known, surgical preparation of the cremaster muscle 
induced leukocyte rolling in postcapillary venules. After 30 
minutes of ischemia and 60 minutes of reperfusion, there 
was a significant increase in numbers of rolling leukocytes as 
compared with sham-operated animals that returned to base-
line values after 120 minutes of reperfusion. PAI-1 deficiency 
did not significantly alter leukocyte rolling during the entire 
reperfusion phase (data not shown). Under baseline conditions 
before I/R, few leukocytes were found firmly adherent to the 
vessel wall of postcapillary venules. In contrast, after 30 min-
utes of ischemia and 120 minutes of reperfusion, there was a 
significant elevation in numbers of firmly adherent leukocytes 
as compared with sham-operated controls. This elevation was 
significantly reduced in PAI-1–deficient animals. Before I/R, 
only few transmigrated leukocytes were detected within the 
perivascular tissue. In response to I/R, the number of trans-
migrated leukocytes was significantly increased as compared 
with sham-operated controls. Similar to our results for leuko-
cyte firm adherence, the postischemic increase in leukocyte 
transmigration was significantly attenuated in PAI-1–deficient 
mice (Figure 1B).
To characterize the functional relevance of leukocyte ver-
sus nonleukocyte PAI-1 for postischemic leukocyte responses, 
we performed cell transfer experiments (Figure 1C). In post-
capillary venules of the postischemic cremaster muscle, the 
numbers of adherent and transmigrated WT donor leukocytes 
were significantly diminished in PAI-1–deficient recipient 
mice as compared with WT mice receiving cells from WT 
donors. Similarly, the numbers of adherent and transmigrated 
cells of PAI-1–deficient donors were significantly lower in 
WT recipients.
As a corollary to the experiments on PAI-1−/− mice, we 
also measured the effects of exogenously applied PAI-1. For 
this purpose, varying doses of murine PAI-1 were directly 
injected into the scrotum of WT mice. After 240 minutes of 
exposure to PAI-1, there was a dose-dependent increase in 
numbers of firmly adherent and transmigrated leukocytes as 
compared with PBS-treated controls, whereas leukocyte roll-
ing was not significantly altered (Figure 2A). Furthermore, 
no significant differences were detected in numbers of intra-
vascularly rolling and firmly adherent as well as transmi-
grated leukocytes between animals receiving an intrascrotal 
injection of active PAI-1 or latent (inactive) PAI-1 lacking 
antifibrinolytic activity (Figure IV in the online-only Data 
Supplement).
Phenotyping Transmigrated Leukocytes
To identify the phenotype of transmigrated leukocytes, immu-
nostaining for CD45 (common leukocyte antigen), Ly-6G 
(neutrophils), and F4/80 (monocytes/macrophages) of crem-
asteric tissue samples was performed. In response to I/R and 
on intrascrotal injection of PAI-1, >85% of transmigrated leu-
kocytes were positive for Ly-6G and ≈15% of transmigrated 
leukocytes were positive for F4/80.
Microhemodynamic Parameters and 
Systemic Leukocyte Counts
To assure intergroup comparability in our in vivo micros-
copy analyses, quantification of inner vessel diameters, blood 
flow velocities, and wall shear rates of analyzed postcapillary 
venules, as well as systemic leukocyte counts, was performed 
(Table I in the online-only Data Supplement). No significant 
differences were detected among all experimental groups.
Role of LRP-1 for PAI-1–Dependent 
Leukocyte Responses
Previous studies have documented that PAI-1 is capable of inter-
acting with LRP-1 which is also known as α-2-macroglobulin 
receptor, apolipoprotein E receptor, or CD91.23–25 To analyze 
the functional relevance of LRP-1 for postischemic leukocyte 
responses, we performed an additional set of experiments. 
Application of RAP (receptor-associated protein), an inhibi-
tor of LRP-1 and other members of the low-density lipopro-
tein receptor family, or antibodies specifically directed against 
LRP-1 significantly reduced postischemic intravascular adher-
ence and transmigration of leukocytes to postischemic tissue 
(Figure VA in the online-only Data Supplement) but did not sig-
nificantly alter intravascular leukocyte rolling (data not shown). 
In line with these results, application of the LRP-1 inhibitor 
RAP or blocking antibodies directed against LRP-1 almost 
completely abolished PAI-1–elicited intravascular adherence 
and transmigration of neutrophils (Figure 2B and 2C). Because 
specific inhibition of LRP-1 achieved >50% of the inhibitory 
effect of RAP, our data suggest that LRP-1 serves as the principal 
receptor of the low-density lipoprotein receptor family for PAI-
1–dependent leukocyte responses. Moreover, PAI-1–dependent 
intravascular adherence of leukocytes was nearly abrogated on 
antibody blockade of the β2 integrins Mac-1/CD11b or (to a 
lesser degree) of LFA-1 (lymphocyte function-associated anti-
gen-1)/CD11a, whereas leukocyte transmigration to the peri-
vascular tissue was significantly reduced on antibody blockade 
of Mac-1/CD11b but not of LFA-1/CD11a (Figure 2D).
Effect of PAI-1 on Activation of 
Neutrophils and Endothelial Cells
Intravascular adherence and the subsequent transmigration of 
leukocytes to the perivascular tissue require interactions of 
leukocyte integrins in higher affinity conformation and their 
endothelial binding partners, such as intercellular adhesion 
molecule (ICAM)-1/CD54 or vascular cell adhesion molecule 
(VCAM-1)/CD106.26–29 Because PAI-1–elicited intravascular 
adherence of neutrophils was strictly dependent on β2 integ-
rins (see above), we hypothesized that PAI-1 induces affinity 
changes in neutrophil β2 integrins.
As a measure of conformational changes of β2 integ-
rins, binding of ICAM-1/CD54 (which predominantly inter-
acts with β2 integrins) to neutrophils (CD45+ CD11b+ Gr-1+ 
CD115- cells) isolated from the peripheral blood of WT mice 
was analyzed by multichannel flow cytometry (Figure 3A). 
We found that the direct stimulation with PAI-1 induced a sig-
nificant increase in the binding of ICAM-1/CD54 to neutro-
phils as compared with PBS-treated controls whereas surface 
expression levels of β 2 integrins/CD18 on neutrophils as well 
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as the binding of VCAM-1/CD106 (which interacts with β1 
integrins) to neutrophils remained unaltered. This increase in 
ICAM-1/CD54 binding was significantly reduced on appli-
cation of the LRP-1 inhibitor RAP, of blocking antibodies 
directed against LRP-1, or of inhibitors of p38, extracellu-
lar signal-regulated kinases 1 and 2, and c-Jun N-terminal 
kinases mitogen-activated protein kinases (MAPK; Figure 3B 
and 3C). Importantly, exposure to MAPK inhibitors or block-
ing anti-LRP-1 antibodies did not significantly alter ICAM-1/
CD54 binding to unstimulated neutrophils (Figure VI in the 
online-only Data Supplement). Similarly, no significant dif-
ferences were detected in CD18 expression or the binding 
capacity for ICAM-1/CD54 or VCAM-1/CD106 between 
WT and PAI-1–deficient neutrophils undergoing exposure to 
PAI-1 (Figure VII in the online-only Data Supplement).
In contrast to these results, exposure to PAI-1 did not 
significantly alter expression levels of ICAM-1/CD54 or 
VCAM-1/CD106 on microvascular endothelial cells (Figure 
VIII in the online-only Data Supplement).
Role of PAI-1 in Postischemic 
Microvascular Leakage
In addition to neutrophil infiltration, microvascular leakage is a 
key event in the pathogenesis of I/R injury that leads to loss of 
intravascular fluid and causes interstitial edema ultimately com-
promising proper reperfusion of postischemic tissue.1,2 The role 
of PAI-1 for the control of microvascular permeability during 
I/R is still unclear. As a measure of microvascular permeability, 
leakage of high molecular weight fluorescein isothiocyanate 
dextran to the postischemic cremaster muscle was analyzed by 
in vivo fluorescence microscopy (Figure 4A). After 30 minutes 
of ischemia and 150 minutes of reperfusion, there was a signifi-
cant increase in the leakage of fluorescein isothiocyanate dex-
tran in WT mice as compared with sham-operated controls. This 
increase was significantly diminished in PAI-1–deficient mice 
and in WT mice treated with blocking anti–LRP-1 antibodies 
(Figure 4A; Figure VB in the online-only Data Supplement).
In a further set of experiments, we sought to evaluate the 
mechanisms underlying the effect of PAI-1 on microvascular 
barrier function in more detail. Intrascrotal injection of PAI-1 
lead to a significant increase in the leakage of fluorescein iso-
thiocyanate dextran as compared with unstimulated controls. 
This increase was almost completely abolished in animals 
depleted from neutrophils. In vitro, exposure of confluent 
HMEC (human microvascular endothelial cell line-1)  endo-
thelial cell layers to PAI-1 induced a dose-dependent reduction 
in macromolecular permeability which was not significantly 
altered on application of the LRP-1 inhibitor RAP (Figure 4B).
Role of PAI-1 in Warm Hepatic I/R Injury
To transfer these findings into a clinically relevant situation, 
the role of PAI-1 was analyzed in a model of warm hepatic 
I/R injury. As a measure of cell death, the number of TUNEL 
(terminal deoxynucleotidyl transferase dUTP nick-end 
labeling)-positive cells was quantified in hepatic tissue sec-
tions. In the liver of sham-operated control mice, only few 
TUNEL-positive cells were detected. In contrast, the number 
of TUNEL-positive cells was significantly elevated on I/R. 
This elevation was significantly diminished in PAI-1–deficient 
mice (Figure 5A). In sham-operated animals, the number of 
leukocytes in the perivascular tissue was found to be low. After 
90 minutes of ischemia and 120 minutes of reperfusion, how-
ever, there was a significant increase in numbers of neutrophils 
(>70% Ly-6G–positive leukocytes) transmigrated to the liver. 
This increase was significantly reduced in PAI-1–deficient 
mice (Figure 5A). In addition, serum levels of transaminases 
were determined in our experiments as a further measure of 
tissue injury. After 90 minutes of ischemia and 120 minutes of 
reperfusion, there was a significant increase in serum levels of 
aspartate aminotransferase and alanine transaminase as com-
pared with sham-operated controls. In line with our concept, 
PAI-1 deficiency significantly attenuated serum levels of ala-
nine transaminase and slightly those of aspartate aminotrans-
ferase; however, the decrease of aspartate aminotransferase 
did not reach statistical significance (Figure 5B).
In vitro, exposure to PAI-1 did not directly affect the via-
bility of primary hepatocytes isolated from WT mice whereas 
the indol alkaloid staurosporine significantly reduced the via-
bility of these cells in a dose-dependent manner (Figure 5C).
Role of PAI-1 for Microvascular 
Thrombus Formation
With regard to its well-known inhibitory action on plasmino-
gen activators, deficiency of PAI-1 might exhibit hyperfibrino-
lytic effects, thereby interfering with microvascular hemostasis 
potentially causing microvascular hemorrhage. Using a model 
of phototoxic injury-induced thrombus formation in cremasteric 
microvessels, the role of PAI-1 for microvascular thrombogen-
esis was evaluated (Figure 6A). We found that onset and ces-
sation times in arterioles and venules of PAI-1–deficient mice 
did not significantly differ from those in WT mice (Figure 6B).
To assure intergroup comparability, fluorescence intensity 
levels, systemic leukocyte counts, and microhemodynamic 
parameters were measured in all experiments. No significant 
differences were observed among the experimental groups 
(Table II in the online-only Data Supplement).
Moreover, postischemic deposition of Alexa488-
conjugated fibrin(ogen) in cremasteric postcapillary venules 
(Figure IXA in the online-only Data Supplement) or hepatic 
sinusoids (Figure IXB in the online-only Data Supplement) did 
not significantly vary between WT and PAI-1–deficient mice.
Effect of TM5275 on Postischemic 
Leukocyte Responses and Liver Injury
In an additional set of experiments, we tested the effect of the 
PAI-1 inhibitor TM5275 on postischemic leukocyte responses. 
Application of this compound 5 minutes before reperfusion 
significantly reduced intravascular adherence and (subsequent) 
transmigration of neutrophils to the perivascular tissue in the 
cremaster muscle of WT mice undergoing 30 minutes of isch-
emia and 120 minutes of reperfusion as compared with vehicle 
treated control animals but did not significantly change leuko-
cyte rolling (Figure X in the online-only Data Supplement). In 
contrast, the number of Ly-6G–positive neutrophils recruited 
to the reperfused liver as well as postischemic serum levels 
of aspartate aminotransferase and alanine transaminase were 
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only slightly but not significantly altered on application of 
TM5275 (Figure XI in the online-only Data Supplement).
Discussion
PAI-1 is increasingly recognized as modulator of nonfibrinolytic 
processes,4,13 including I/R injury.30–35 The underlying mecha-
nisms remain poorly understood. In the postischemic inflamma-
tory response, leukocytes accumulate in the microvasculature 
and infiltrate the perivascular tissue, thereby compromising 
proper reperfusion and amplifying the ischemic tissue injury.1,2 
To characterize the contribution of PAI-1 to these events, we 
used different in vivo and ex vivo microscopy techniques in 
genetically modified mice. In I/R injury, PAI-1 was found to be 
presented on the endothelium of postcapillary venules as well as 
on infiltrating neutrophils. Together with circulating PAI-1, this 
protease inhibitor is thought to bind to cell surface glycosami-
noglycans which enhances its biological activity.36,37 As a con-
sequence of this process, PAI-1 derived from both leukocytes 
and nonleukocytic sources promoted postischemic neutrophil 
adherence to the microvascular endothelium and supported the 
subsequent transmigration of these immune cells to the intersti-
tial tissue. Our findings extend previous observations in which 
blockade of PAI-1 was associated with reduced leukocyte infil-
tration of the reperfused tissue on postischemic lung injury.32
Beyond its inhibitory effects on the plasminogen activators 
tPA and urokinase-type plasminogen activator, PAI-1 interacts 
with LRP-1, a member of the low-density lipoprotein recep-
tor family, which serves as a multifunctional scavenger and 
signaling receptor in various biological processes,23–25 includ-
ing leukocyte trafficking.38 Because LRP-1 is expressed on the 
surface of neutrophils, we hypothesized that PAI-1 mediates 
postischemic neutrophil responses via this receptor protein. In 
our experiments, we show that blockade of LRP-1 significantly 
diminishes intravascular adherence and subsequent transmi-
gration of neutrophils to postischemic tissue. Moreover, we 
found that exogenously administered, recombinant PAI-1 is 
capable of inducing neutrophil responses, which were strictly 
dependent on LRP-1. In this context, we did not detect any 
differences on the capability to elicit neutrophil extravasation 
between active PAI-1 and latent PAI-1 lacking antifibrinolytic 
activity indicating that this protease inhibitor recruits neutro-
phils independently of its well-known antifibrinolytic proper-
ties. Thus, our data suggest that endothelially presented PAI-1 
acts as an inflammatory mediator that directs circulating neu-
trophils to postischemic tissue by engaging LRP-1.
Toward a more comprehensive, mechanistic understand-
ing of these processes, we sought to elaborate the molecular 
basis underlying PAI-1–dependent neutrophil responses in 
further experiments. Leukocyte adherence to microvascu-
lar endothelial cells is facilitated by interactions of leuko-
cyte integrins with their endothelial binding partners of the 
immunoglobulin superfamily (eg, ICAM-1/CD54, VCAM-1/
CD106). This process requires the induction of higher affin-
ity conformations of leukocyte integrins typically elicited by 
endothelially presented chemokines or other inflammatory 
mediators.26–29 Consequently, endothelially presented PAI-1 
might initiate conformational changes in neutrophil integrins 
to regulate postischemic neutrophil responses. In line with 
this concept, we document that PAI-1 induces higher affinity 
conformations of β2 integrins in neutrophils but does not acti-
vate microvascular endothelial cells. These events were found 
to require LRP-1 and MAPK-dependent signaling pathways. 
Moreover, we show that PAI-1–dependent adherence of neu-
trophils to the microvascular endothelium (but not intravascu-
lar rolling) is mediated by the β2 integrins LFA-1/CD11a and 
Mac-1/CD11b. In summary, these results indicate that PAI-1 
promotes neutrophil trafficking to postischemic tissue through 
interaction with LRP-1 in intravascularly rolling neutrophils 
which, in turn, induces conformational changes of neutrophil 
β2 integrins via MAPK-dependent signaling pathways.
In addition to leukocyte recruitment, endothelial dysfunc-
tion and enhanced microvascular permeability represent key 
factors of I/R injury.1,2 With respect to previous reports docu-
menting the participation of PAI-1 in the regulation of vascu-
lar permeability during cardiac fibrosis39 and ischemic brain 
injury,33 we hypothesized that PAI-1 is involved in the control 
of postischemic microvascular leakage. Here, we demonstrate 
that PAI-1 deficiency or blockade of its receptor LRP-1 potently 
protect the microvasculature from its postischemic loss of bar-
rier function. Conversely, we found that exogenous adminis-
tration of recombinant PAI-1 induced a significant elevation in 
microvascular permeability. Importantly, neutrophil depletion 
completely abolished PAI-1–elicited microvascular leakage in 
vivo whereas addition of recombinant PAI-1 to microvascular 
endothelial cell layers in vitro even reduced their macromo-
lecular permeability in an LRP-1–independent manner. Our 
findings, therefore, suggest that PAI-1 promotes postischemic 
microvascular leakage indirectly through the recruitment of 
neutrophils but does not directly affect microvascular integrity. 
In this context, it has previously been reported that intravascu-
larly adherent neutrophils increase microvascular permeability 
through secreted products (eg, chemokines/cytokines or reac-
tive oxygen species) as well as via adhesion-dependent pro-
cesses involving β2 integrins and endothelial ICAM-1/CD54.40
To transfer these findings into a clinically more relevant 
situation, we used a hepatic I/R injury model. In our experi-
ments, deficiency of PAI-1 significantly diminished neutro-
phil infiltration of the postischemic liver. These effects were 
associated with a strong attenuation of hepatic I/R injury as 
indicated by reduced numbers of apoptotic/necrotic hepato-
cytes and decreased serum levels of transaminases. Because 
PAI-1 did not exhibit direct cytotoxic or cytoprotective effects 
on primary hepatocytes in vitro, our results suggest that the 
immediate specific and effective blockade of PAI-1 in the 
acute inflammatory response on I/R protects from postisch-
emic liver injury via inhibition of neutrophil-mediated cell 
death. Noteworthy, however, prolonged blockade (genetic 
deficiency) of PAI-1 resulted in accelerated myocardial rup-
ture,41 enhanced cardiac fibrosis,42 and increased inflammatory 
cell influx35 on experimental myocardial infarction. In con-
trast, pharmacological inhibition of PAI-1 showed no effect on 
postischemic liver injury or cardiac remodeling,34 whereas—
in line with our results—deficiency of this serpin was asso-
ciated with reduced tissue injury early on I/R of the lung.32 
Similarly, in acute cerebral I/R, administration of an inhibitor 
directed against PAI-1 and thrombin activatable fibrinolysis 
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inhibitor led to mitigated brain damage and improved func-
tional outcomes.30,31 Hence, the appropriate timing for effec-
tive interference with the action of PAI-1 seems to be critical 
for its successful application in the treatment of I/R injury.
Manipulating the fibrinolytic system might not only cause 
side effects on tissue remodeling (because of the modulation of 
plasmin-dependent activation of matrix metalloproteinases) but 
might also lead to enhanced thrombus formation (as a conse-
quence of reduced fibrinolysis)43–47 or to hematoma formation 
(as a result of exaggerated fibrinolysis).48 All these condi-
tions might compromise postischemic organ function. Recent 
observations, however, indicate that pharmacological blockade 
of PAI-1 results in a prominent profibrinolytic effect without 
increased bleeding from larger vessels.31 Because leukocytes are 
critically involved in thrombus formation in larger vessels,49,50 
these effects might not only be explained by hyperfibrinoly-
sis but also be because of a reduction of leukocyte-mediated 
prothrombotic effects in this particular pathological context. 
To evaluate the role of PAI-1 in microvascular hemostasis, we 
used a model of thrombosis elicited by photochemical injury. In 
these experiments, we were able to demonstrate that deficiency 
of PAI-1 does not alter thrombogenesis in the microvasculature. 
Moreover, PAI-1 deficiency was not associated with increased 
deposition of fibrin(ogen) on the postischemic microvascular 
endothelium. Consequently, these data indicate that the imme-
diate interference with PAI-1 might provide a safe strategy for 
the prevention and treatment of early I/R injury.
In conclusion, our experimental findings identify a pre-
viously unrecognized function of PAI-1 as an inflammatory 
mediator that is rapidly deposited on the microvascular endo-
thelium on I/R and subsequently induces conformational 
changes in β2 integrins of intravascularly rolling neutro-
phils. These events are mediated through LRP-1 and MAPK-
dependent signaling pathways that, in turn, promote 
accumulation of neutrophils in the reperfused tissue. During 
this process, neutrophils disrupt endothelial junctions and 
support the postischemic microvascular leakage. Conversely, 
deficiency of PAI-1 effectively attenuated neutrophil recruit-
ment, microvascular dysfunction, and tissue injury on experi-
mental I/R without exhibiting side effects on microvascular 
hemostasis. Our findings provide novel insights into the non-
fibrinolytic functions of the fibrinolytic system and suggest 
the blockade of PAI-1 (eg, by angiotensin-converting enzyme 
inhibitors lowering serum levels of PAI-151,52 or specific and 
effective PAI-1 inhibitors) as a promising strategy for the pre-
vention and treatment of I/R injury.
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Highlights
• Plasminogen activator inhibitor-1 (PAI-1) rapidly accumulates on the endothelium of the postischemic microvasculature.
• Deposited PAI-1 subsequently directs neutrophils to postischemic tissue by inducing affinity changes in integrins of these immune cells.
• PAI-1 causes affinity changes of neutrophil integrins via interaction with low-density lipoprotein receptor–related protein-1 and mitogen-
activated protein kinases–dependent signaling pathways.
• PAI-1–dependent extravasation of neutrophils from the microvasculature to the reperfused tissue promotes microvascular leakage.
• Deficiency of PAI-1 effectively reverses ischemia–reperfusion injury without exhibiting side effects on microvascular hemostasis.
